Results 141 to 150 of about 50,558 (217)

Is it "Time to Eliminate" Time to Elimination of Symptoms as a Primary Trial End Point for Drugs Targeting Respiratory Viruses? [PDF]

J Infect Dis
Schiffer JT, Esmaeili S, Owens K, Boeckh M, Waghmare A.   +4 more
europepmc   +1 more source

Pharmacokinetic drug-drug interaction between the COVID-19 3CL protease inhibitor GST-HG171 and itraconazole in healthy subjects. [PDF]

Antimicrob Agents Chemother
Li X, Li B, Wang M, Wang J, Lu J, Mao J, Zhang T, Tang Y, Yan W, Li C, Zhang G, Ding Y.   +11 more
europepmc   +1 more source

Navigating Therapeutic Frontiers: A Meta-review and Meta-analysis of COVID-19 Treatment Options. [PDF]

J Res Pharm Pract
Mousavi S, Ardekani MB, Feizi A.
europepmc   +1 more source

A Phase 1 Multiple-Dose, Open-Label, Pharmacokinetic Study of Nirmatrelvir/Ritonavir in Healthy Lactating Women. [PDF]

Clin Transl Sci
Gerhart J, Cheruvu N, Pelletier K, Matschke K, Shi H, Mfopou JK, Hammond J, Singh RSP.   +7 more
europepmc   +1 more source

Pharmacokinetics of Nirmatrelvir/Ritonavir after Multiple Administration in a Phase 1, Open-Label Study in Healthy Chinese Adults and Compared with Non-Chinese Participants. [PDF]

Clin Drug Investig
Li N, Yu J, Wu J, Zhang J, Ma Y, Zhang C, Han X, Gerhart J, Cong S.   +8 more
europepmc   +1 more source

Patient Characteristics and Healthcare Resource Use among Patients With COVID-19 Receiving Treatment with Nirmatrelvir/Ritonavir (PAXLOVID™) in the Kingdom of Saudi Arabia. [PDF]

Pulm Ther
Alraddadi BM, Almaghrabi RS, Bosaeed M, Kamal M, Hassanien A, Hammam H, Zanotti G, Ikizler BK, d'Hellencourt FL, Spinardi JR, Wang L, Kyaw MH.   +11 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions With the Antibody-Drug Conjugate Trastuzumab Deruxtecan. [PDF]

CPT Pharmacometrics Syst Pharmacol
Watanabe A, Gill KL, Chen KF, Jones HM, De Sousa Mendes M, Gardner I, Kotsuma M.   +6 more
europepmc   +1 more source

Repurposing anti-retroviral drugs to treat NF2-related tumours: a protocol for a phase 0 trial (RETREAT). [PDF]

BMJ Open
Campbell S, Beaney K, Hosking J, Sorrell L, Allgar V, Aspinall PJ, Ammoun S, Evans DG, Hanemann CO, Kingdon S.   +9 more
europepmc   +1 more source

Major protease inhibitor drug resistance mutations among patients with virological failure on second-line antiretroviral therapy in Zimbabwe: a retrospective cross-sectional study. [PDF]

Virol J
Mayini J, Washaya T, Manasa J, Zumbika E, Munyati S, Shoko R, Dahlke C, Kouamou V.   +7 more
europepmc   +1 more source